Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Evaluation of Fisetin to Reduce Systemic Senescence Indices: A Randomized Controlled Dosing Equivalence Study

Authors not listed

Steadman Philippon Research Institute · 2023

Abstract

This is a prospective, randomized clinical trial to evaluate the ability of the supplement, Fisetin, to safely reduce systemic senescence(definition) (aging) indices assessed in peripheral blood.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-13 MST

Cite this

APA
Anonymous. (2023). Evaluation of Fisetin to Reduce Systemic Senescence Indices: A Randomized Controlled Dosing Equivalence Study. <em>Steadman Philippon Research Institute</em>. https://clinicaltrials.gov/study/NCT07918261
Vancouver
Anonymous. Evaluation of Fisetin to Reduce Systemic Senescence Indices: A Randomized Controlled Dosing Equivalence Study. Steadman Philippon Research Institute. 2023.
BibTeX
@misc{anon2023Evalua, title = {Evaluation of Fisetin to Reduce Systemic Senescence Indices: A Randomized Controlled Dosing Equivalence Study}, author = {Anonymous}, journal = {Steadman Philippon Research Institute}, year = {2023}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings